metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus docetaxel
	pembrolizumab (10mg/kg)
	KEYNOTE-010 (P:10 mg/kg), 2016 Lancet 2016;387:1540-50 Ann. Oncol. 2019; 30:281-289 J Thorac Oncol 2019 May;14(5):793-801. NCT01905657	RCT	mNSCLC - L2 - PDL1 positive	pembrolizumab 10 mg/kg	docetaxel	patients with previously treated (one line or more) non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells	346 / 343	high	conclusif
	KEYNOTE-010 (P:10 mg/kg ; PDL1>50%), 2016 Lancet 2016;387:1540-50 Ann. Oncol. 2019; 30:281-289 J Thorac Oncol 2019 May;14(5):793-801. NCT01905657	RCT	mNSCLC - L2 - PDL1 positive	pembrolizumab 10 mg/kg	docetaxel	patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 50% of tumour cells	151 / 152	high	conclusif